Interviews, expert presentations, and the latest treatment data — all from this year’s largest endocrinology meeting.
From J D Faccinetti co-founder – The annual international endocrine conference ENDO 2026, which just ended in Chicago, yielded a ton of information and new developments. The meeting drew over 7,000 attendees, nearly 2,500 abstracts, and more than 200 sessions, with daily plenaries on genomics/sex differences/physiology, endocrine regulation in metabolism, and molecular mechanisms in hormone signaling. The expo floor featured more than 100 exhibitors and nearly 2,000 poster abstracts. PWN and AWN were present to report on some of the more important developments.
We recorded 16 interviews with doctors, scientists, patient advocates, and industry representatives, so please stay tuned; they will be published in the next few days. Great, interesting information to come.
Of particular note was Dr. Richard Auchus, Professor of Medicine at the University of Michigan, on the connection between Cortisol, difficult-to-treat hypertension, and type 2 diabetes, as well as a new drug for Congenital Adrenal Hyperplasia (CAH), a subject that has been extensively covered in our publications. Click here for more on that.
Dr. Kevin Yuen from Barrow Neurological Institute in Phoenix, AZ gave us an excellent summary of his presentation titled “Pituitary Tumor Survivorship: Transitioning from Pediatric to Adult Endocrine Care.” This is a topic that’s a real pain point in pituitary care: what happens to kids with pituitary tumors once they age out of pediatric care and move into the adult system.
Dr. Lewis Blevins presented on the evidence, development, and implications in hypercortisolism and Cushing’s syndrome, and new guidelines for the treatment of Central Diabetes Insipidus also known as AVP deficiency.
From the industry perspective there were several presentations on the new octreotide 1-month and 3-month formulations from Camurus and Debiopharm, respectively. You don’t want to miss those. Lots of great information, new treatment options, and things to watch as they become available. You can also sign up for a Clinical trial.
In the great news column, the acromegaly pill keeps working, even after 2 years. Crinetics shared new results for paltusotine (brand name PALSONIFY), the once-daily pill for acromegaly. People who switched from their monthly injection to the pill stayed just as well-controlled two years later, with their IGF-1 levels barely moving. For some patients who hadn’t been treated before, their pituitary tumors actually got smaller, more than 20% smaller in 7 out of 83 patients who had follow-up scans.
In the ADRENAL space, the new CAH pill (Crenessity) is holding up well after 2 years. Neurocrine showed that adults taking crinecerfont (Crenessity) for congenital adrenal hyperplasia (CAH) were able to take lower doses of steroids long-term. That also came with real benefits: less weight gain, better insulin sensitivity, and healthier bones. Kids on the drug showed similar improvements, plus better growth patterns. No new safety concerns showed up after two years of use.
First-ever data on Crenessity in a rarer form of CAH. Most CAH research focuses on the most common type. This was the first look at how the drug works in patients with a less common type of CAH (caused by a different enzyme problem) — good news for a group that’s had very little data of their own until now. Stay tuned for more info, and listen to Dr. Auchus’ interview for details on this new drug.
A new adrenal drug in the pipeline is showing promise. Crinetics shared early results for a new pill called atumelnant, also for CAH. After just 12 weeks, it shrank the adrenal glands and quickly brought down hormone levels that are usually too high in CAH patients. It’s earlier-stage than Crenessity, but it’s one to watch.
Isturisa (osilodrostat): Recordati’s oral pill for Cushing’s syndrome, which works by blocking cortisol production at the source. They presented four poster presentations drawing on pooled clinical trial and real-world data to look at quality of life, biochemical control, and clinical outcomes across a range of Cushing’s syndrome patients, including those with milder disease. A study called LINC CARE is looking at whether osilodrostat can help patients whose high blood pressure is caused by Cushing’s-related excess cortisol, even when other medications haven’t worked.
Chiesi Rare Disease presented survey findings shedding light on psychological burdens (like altered body image) and the lack of mental health support for patients and care partners.
Watch your inbox and stay tuned for the interviews. If you want to receive the latest news, please click here to subscribe to PWN and here to subscribe to AWN. All we need is your email.
© 2026, J D Faccinetti. All rights reserved.